Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer
Curis, Inc. (NASDAQ: CRIS) announces the 3rd Annual Symposium on IRAK4 in Cancer, scheduled for September 26, 2024. The virtual event, hosted by Dr. Eric S. Winer and Dr. Grzegorz S. Nowakowski, will focus on IRAK4 as an emerging target in treating hematologic malignancies and solid tumors. The symposium will feature updated data for 10 evaluable R/R PCNSL patients as of July 10, 2024. Curis aims to enroll 15-20 patients in the PCNSL study by year-end.
The event will bring together experts to discuss the potential of IRAK4 inhibition in cancer, including current clinical studies of emavusertib (CA-4948), Curis's orally available, small molecule IRAK4 inhibitor. Presentations will cover the biology of the IRAK4 pathway and its inhibition in cancer therapy development. The symposium is free and open to the public, offering insights into this promising area of oncology research.
Curis, Inc. (NASDAQ: CRIS) annuncia il 3° Simposio Annuale su IRAK4 nel Cancro, programmato per il 26 settembre 2024. L'evento virtuale, ospitato dal Dr. Eric S. Winer e dal Dr. Grzegorz S. Nowakowski, si concentrerà su IRAK4 come obiettivo emergente nella cura delle neoplasie ematologiche e dei tumori solidi. Il simposio presenterà dati aggiornati per 10 pazienti R/R PCNSL fino al 10 luglio 2024. Curis mira a reclutare 15-20 pazienti nello studio PCNSL entro la fine dell'anno.
L'evento riunirà esperti per discutere il potenziale dell'inibizione di IRAK4 nel cancro, inclusi gli attuali studi clinici su emavusertib (CA-4948), l'inibitore di IRAK4 di Curis disponibile per via orale. Le presentazioni tratteranno la biologia della via dell'IRAK4 e la sua inibizione nello sviluppo della terapia oncologica. Il simposio è gratuito e aperto al pubblico, offrendo approfondimenti su quest'area promettente della ricerca oncologica.
Curis, Inc. (NASDAQ: CRIS) anuncia el 3er Simposio Anual sobre IRAK4 en Cáncer, programado para el 26 de septiembre de 2024. El evento virtual, organizado por el Dr. Eric S. Winer y el Dr. Grzegorz S. Nowakowski, se centrará en IRAK4 como un objetivo emergente en el tratamiento de malignidades hematológicas y tumores sólidos. El simposio presentará datos actualizados para 10 pacientes R/R PCNSL hasta el 10 de julio de 2024. Curis tiene como objetivo inscribir de 15 a 20 pacientes en el estudio de PCNSL para finales de año.
El evento reunirá a expertos para discutir el potencial de la inhibición de IRAK4 en el cáncer, incluidos los estudios clínicos actuales de emavusertib (CA-4948), un inhibidor de IRAK4 de Curis disponible por vía oral. Las presentaciones cubrirán la biología de la vía de IRAK4 y su inhibición en el desarrollo de terapias contra el cáncer. El simposio es gratuito y está abierto al público, ofreciendo perspectivas sobre esta prometedora área de investigación oncológica.
Curis, Inc. (NASDAQ: CRIS)는 2024년 9월 26일로 예정된 암에서의 IRAK4에 관한 제3회 연례 심포지엄을 발표했습니다. 에릭 S. 와이너 박사와 그제고르즈 S. 노와코프스키 박사가 주최하는 이번 가상 이벤트는 혈액 악성 종양 및 고형 종양 치료에 있어 IRAK4의 떠오르는 표적에 초점을 맞출 것입니다. 심포지엄에서는 2024년 7월 10일 기준으로 10명의 R/R PCNSL 환자에 대한 업데이트된 데이터가 제공될 예정입니다. Curis는 연말까지 PCNSL 연구에 15-20명의 환자를 등록할 계획입니다.
이 이벤트는 암에서 IRAK4 억제의 잠재력에 대해 논의하기 위해 전문가들을 모이게 하며, Curis의 경구용 작은 분자 IRAK4 억제제인 emavusertib (CA-4948)의 현재 임상 연구도 포함됩니다. 발표는 IRAK4 경로의 생물학 및 암 치료 개발에서의 억제에 대해 다룰 것입니다. 심포지엄은 무료이며 공개되어 있어 이 유망한 종양학 연구 분야에 대한 통찰력을 제공합니다.
Curis, Inc. (NASDAQ: CRIS) annonce le 3ème Symposium Annuel sur IRAK4 dans le Cancer, prévu pour le 26 septembre 2024. L'événement virtuel, organisé par le Dr Eric S. Winer et le Dr Grzegorz S. Nowakowski, mettra l'accent sur IRAK4 en tant que cible émergente pour le traitement des malignités hématologiques et des tumeurs solides. Le symposium présentera des données mises à jour pour 10 patients R/R PCNSL jusqu'au 10 juillet 2024. Curis vise à inscrire 15 à 20 patients dans l'étude PCNSL d'ici la fin de l'année.
L'événement rassemblera des experts pour discuter du potentiel de l'inhibition d'IRAK4 dans le cancer, notamment des études cliniques actuelles concernant emavusertib (CA-4948), l'inhibiteur d'IRAK4 disponible par voie orale de Curis. Les présentations couvriront la biologie de la voie IRAK4 et son inhibition dans le développement des thérapies anticancéreuses. Le symposium est gratuit et ouvert au public, offrant des aperçus sur ce domaine prometteur de la recherche en oncologie.
Curis, Inc. (NASDAQ: CRIS) kündigt das 3. jährliche Symposium zu IRAK4 bei Krebs an, das für den 26. September 2024 geplant ist. Die virtuelle Veranstaltung, die von Dr. Eric S. Winer und Dr. Grzegorz S. Nowakowski geleitet wird, wird sich auf IRAK4 als aufkommendes Ziel bei der Behandlung von hämatologischen Malignitäten und soliden Tumoren konzentrieren. Das Symposium wird aktualisierte Daten zu 10 bewertbaren R/R PCNSL-Patienten bis zum 10. Juli 2024 enthalten. Curis plant, bis Jahresende 15-20 Patienten in die PCNSL-Studie aufzunehmen.
Das Event bringt Experten zusammen, um das Potenzial der IRAK4-Inhibition bei Krebs zu diskutieren, einschließlich der aktuellen klinischen Studien zu emavusertib (CA-4948), einem oral verfügbaren IRAK4-Inhibitor von Curis. Die Präsentationen werden die Biologie des IRAK4-Signalwegs und dessen Inhibition bei der Entwicklung von Krebstherapien abdecken. Das Symposium ist kostenlos und für die Öffentlichkeit zugänglich und bietet Einblicke in dieses vielversprechende Gebiet der Onkologieforschung.
- Curis is on track to enroll 15-20 patients in the PCNSL study by year-end
- The symposium will present updated data for 10 evaluable R/R PCNSL patients
- Curis is positioning itself as a leader in IRAK4 inhibition in oncology with emavusertib
- None.
Symposium hosted by Eric S. Winer, MD, and Grzegorz S. Nowakowski, MD
Updated data for 10 evaluable patients in Curis's PCNSL study
Experts will present at the virtual meeting, free and open to the public, on September 26, 2024
Hosted by Dr. Eric S. Winer (Dana-Farber Cancer Institute) and Dr. Grzegorz S. Nowakowski (Mayo Clinic Comprehensive Cancer Center), this symposium will focus on IRAK4, an emerging target in the treatment of hematologic malignancies and solid tumors. Experts will discuss the promise of IRAK4 inhibition in cancer, including current clinical studies of emavusertib and opportunities for future development.
Symposium presentations will include updated data for 10 evaluable R/R PCNSL patients as of the July 10, 2024 cutoff date. The Company continues to enroll patients in the PCNSL study and is on track to enroll 15-20 patients by year-end.
"As the leader in IRAK4 inhibition in oncology with emavusertib, we are honored to provide a forum for discussing the biology of the IRAK4 pathway and IRAK4 inhibition in the research and development of therapies to benefit patients living with cancer," said James Dentzer, President, and Chief Executive Officer of Curis.
Symposium co-chairs:
- Eric Winer, MD, Clinical Director and Adult Leukemia Institute Physician, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School
- Grzegorz Nowakowski, MD, Professor of Oncology and Medicine, Division of Hematology, Deputy Director of Mayo Clinic Comprehensive Cancer Center for Clinical Research and Vice-Chair of Division of Hematology
Joining our hosts will be the following speakers and participants:
- Bently Doonan, MD, Assistant Professor, Division of Hematology and Oncology, University of
Florida College of Medicine - Andrés Ferreri, MD, Contract Professor of Oncology, University Vita-Salute San Raffaele; Head of the Lymphoma Unit, I.R.C.C.S. Ospedale San Raffaele
- Klaus Metzeler, MD, Professional of Translational Hematology, University of
Leipzig - Guillermo Garcia-Manero, MD, Professor, Chief of Section of Myelodysplastic Syndromes, Deputy Chair of Translational Research and Fellowship Program Director Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- Marina Konopleva, MD, PhD, Professor of the Department of Oncology, Professor of the Department of Molecular Pharmacology, and Miriam Mandel Faculty Scholar in Cancer Research, Albert Einstein College of Medicine
- Kian Lim, MD, PhD, Associate Professor, Department of Medicine, Division of Oncology, Washington University School of Medicine in
St. Louis - Lakshmi Nayak, MD, Director of the Center for CNS Lymphoma Dana‑Farber Cancer Institute; Associate Professor of Neurology, Harvard Medical School
- Han Tun, MD, Hematologist, Internist, Oncologist, Departments of Hematology and Mayo Clinic Comprehensive Cancer Center
To learn more about this free-to-attend symposium and register, please visit https://cvent.me/kDaoDK
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-announces-the-3rd-annual-symposium-on-irak4-in-cancer-302254943.html
SOURCE Curis, Inc.
FAQ
When is Curis's 3rd Annual Symposium on IRAK4 in Cancer taking place?
What is the focus of Curis's (CRIS) symposium on IRAK4 in cancer?
How many PCNSL patients' data will be presented at Curis's (CRIS) symposium?
What is Curis's (CRIS) enrollment target for the PCNSL study by year-end?
